Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 478.70M P/E - EPS this Y 34.30% Ern Qtrly Grth -
Income -284.69M Forward P/E -2.24 EPS next Y 34.60% 50D Avg Chg -30.00%
Sales 27.71M PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book 1.36 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 6.62 Shares Outstanding 48.70M 52W Low Chg 8.00%
Insider Own 4.33% ROA -17.12% Shares Float 37.99M Beta 0.95
Inst Own 72.14% ROE -126.41% Shares Shorted/Prior 4.27M/4.31M Price 10.06
Gross Margin - Profit Margin - Avg. Volume 917,950 Target Price 19.18
Oper. Margin -425.99% Earnings Date Aug 1 Volume 1,168,323 Change -5.27%
About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V. News
07:05 AM uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
11/08/24 Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
11/07/24 What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates
11/06/24 uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/05/24 UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
11/05/24 UniQure: Q3 Earnings Snapshot
11/05/24 uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
10/30/24 Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
10/29/24 UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
10/15/24 uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
10/15/24 uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
10/09/24 Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
09/23/24 uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
09/13/24 uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
08/15/24 uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
08/03/24 uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
08/01/24 UniQure restructuring to claim 300 jobs
08/01/24 UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
08/01/24 UniQure: Q2 Earnings Snapshot
08/01/24 uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
QURE Chatroom

User Image Tumble51 Posted - 57 minutes ago

$QURE The NEWSSSSS is NO NEWSSSSS ….MATT K is still the CEO without. CLUE

User Image Scanners_Free Posted - 4 hours ago

$QURE NEWSSSSSSSS

User Image Dkll303 Posted - 1 day ago

$QURE Still POS ..should be the symbol !! But the NYSE , knows it is siht

User Image Dkll303 Posted - 1 day ago

$QURE You have your post all fcuked up..it is called TRUTH TRUTH….QURE IS CRAP IN A BROWN PAPER BAG, PEDDLED BY MATT K , AND HIS IQ IS EXTREMELY LOW. TRUTH TRUTH HE DOES HAVE HATERS, TO THE TUNE OF 1M today, hahahaha

User Image Dkll303 Posted - 1 day ago

$QURE BIG F’IN DEAL …900K shares sold off ..they know Matt Kapusta will fuck it up, like he did with their hemophilia drug , lol

User Image AnalRetort Posted - 1 day ago

$QURE AMT-130 significantly slowed the progression of Huntington’s disease in a dose-dependent manner. After 24 months of observation, the higher dose of the gene therapy slowed disease progression by 80% relative to the external controls. This effect was statistically significant, with a p-value of 0.007, according to uniQure. https://www.biospace.com/drug-development/uniqure-wins-first-fda-rmat-in-huntingtons-disease-after-strong-phase-i-ii-data

User Image jewell69 Posted - 2 days ago

@tttggg @Wrangler4 which two are u talking about $QURE and ??? It used 2 b a tie between Salveen Richter and gena wang as my favorites; lately it is is Ms Richter = no touch on $QURE

User Image tttggg Posted - 2 days ago

@Wrangler4 @jewell69 why compare the two? $QURE much better…

User Image AnalRetort Posted - 2 days ago

$QURE FDA is only requiring 30 patient study for dmd for RGNX's gene therapy to get aa. No control. QURE has 39 and meeting in the next two weeks. I really think QURE gets AA here, the worst case scenario would be a short 30 person study no controls, but I don't even think that is needed. We have the need, we have the bio marker, the safety is the one issue, but the company has worked it out on the last 12 patients and considering the severity of the condition --- AA. LFG. Load up!

User Image jewell69 Posted - 3 days ago

$QURE close 6.06 on 11/5 earnin_s date; spike to > 7.85 on 11/11 back down to 6.21 in basketball, its called a head fake (indeed, today we saw harvard lose to CU today in Boulder, live !) need to study

User Image jewell69 Posted - 3 days ago

$QURE so lucky my last trades (Im out) Shares +601.000 b 9/30 Price $5.10 Amount -$3,065.10 Settlement date Oct-01-2024 Shares -952.000 Price $5.51 s 10/6 Amount $5,242.51 Fees $0.15 Settlement date Oct-07-2024 friday 11/15 close 6.70 must _ave missed run up to 7.75 on 11/11 !

User Image Wrangler4 Posted - 5 days ago

$QURE ..rose coloured glasses always make things “ not so bad “ Then Matt kapusta , arrives and everything goes to siht..just like this has for 4 fcukin years Selling of parts ( drug for 2.5B , 400M of that left , Lexington plant for cash ) maybe Matt’s desk next ! Until nothing is left L

User Image Wrangler4 Posted - 5 days ago

$ADAP where is @jewell69 ..the star of ADAP and the train wreck $QURE !!!! The guru of the two ..hahaha

User Image jackcoltrain Posted - 6 days ago

$GLPG $QURE $SPRB $LOGC better than a savings account

User Image HScottMatusow Posted - 1 week ago

Ok, $BMY was in $QURE in 2015, same amount of shares but have become diluted under 5% of the class, so this is a nothing burger. I'm curious why BMY is not listed under company's institutional investor roster though. This filing is just procedural, so ignore my other post. https://uniqure.gcs-web.com/node/11881/html

User Image DesertDweller93 Posted - 1 week ago

@prevclose $BMY has owned those $QURE shares since 2015 when they originally owned 9.9% as a result of a partnership. Since then, due to shares being issued over the years, the % dropped to less than 5%. BMY was late in filing the form as it should have been filed earlier this year when their ownership % was less than 5%.

User Image HScottMatusow Posted - 1 week ago

$QURE https://uniqure.gcs-web.com/node/11881/html. To the best of my knowledge, $BMY here is a new investor - likely means a co-dev is coming, acquisition down the road, likely next year.

User Image prevclose Posted - 1 week ago

$QURE 13g. Brutal Meyers Squib has $2.3 million shares. Is this a new buy or old news. Could be a potential buyout, maybe?

User Image HScottMatusow Posted - 1 week ago

$QURE Jan 25, $12 seeing a ton of call action here, most were bought including 2 lots of over 600 and 400. So, we can see that was a stop run yesterday. Looking good, let's get a surprise PR to the upside!

User Image SkSk_ Posted - 1 week ago

$QURE these are wild. small premium but very deep OTM. Company did say they expect to give an update on Huntingtons AA around JPM conf (13-16JAN) so theres a decent chance these hit. think April strikes are the better play to catch more upside.. going to start accumulating some.

User Image tttggg Posted - 1 week ago

$QURE you saved my day…

User Image Tumble51 Posted - 1 week ago

$QURE That didn’t take long to fall the fcuk apart again, RIGHT WAINWRIGHT..hahahaha Mike King ? Still pumping gas ? or pumping tires now

User Image AnalRetort Posted - 1 week ago

$QURE Update on Huntington’s Disease Program Webcast link: https://wsw.com/webcast/guggen/qure/1964809 UniQure remains bullish on potential approval for their Huntington’s disease therapy, with promising FDA interactions ahead. Due to RMAT designation, they have a Type B multidisciplinary meeting set for late November, marking their first formal engagement with the FDA since the IND. A briefing package has been submitted, and the company anticipates disclosing FDA alignment progress in the first half of 2025, around the time of the JP Morgan conference. Key Takeaways: Expert Enthusiasm: Huntington's disease KOLs are highly optimistic, noting that a blinded study may not be necessary due to significant results observed in functional composite endpoints, which track cognitive and behavioral progress. Comparative Data: KOLs have cited strong evidence when comparing to a propensity-weighted natural history, reinforcing the credibility of the observed effects. Neurofilament Light Chain (NFL) Data:

User Image HScottMatusow Posted - 1 week ago

I've been trading and investing for 25 years, and I've never seen such a manipulated stock as $QURE. I have never seen a straight down drop on light volume with no news like this - I've only seen this in very low floaters. It's a concerted effort to wipe-out options IV

User Image Wrangler4 Posted - 1 week ago

$QURE Is Matt fired yet….bag of wind.

User Image Dkll303 Posted - 1 week ago

$QURE another lie

User Image Dkll303 Posted - 1 week ago

$QURE still dog siht !!! lol

User Image Barbann Posted - 1 week ago

$QURE good vol.

User Image AnalRetort Posted - 1 week ago

$QURE Hi Random moron on the internet, it's anal retort - you are probably not worth my time but today I bought $9 calls for April 2025 check the volume on the tape it if you don't believe me I didn't even get a great deal. I paid $1.6 each. Meaning I'm so confident that I don't even break even until this stock is at a 52 week high of 10.6. This is in addition to Jan calls and common shares. This shows my conviction and sincerity that I truly believe $qure will get the green light to go for AA from Peter Marks at the FDA. Lets be real this is a regulatory trade, and it's high risk, be smart about your position size if you cannot handle the swings.

User Image Dkll303 Posted - 1 week ago

$QURE …Stay the F away from this Stock ….the hype is to con you into it and it is going nowhere for at least 2 years ….there is no revenue , royalties on their drug don’t even cover the costs ..AVOID !

Analyst Ratings
Cantor Fitzgerald Overweight Sep 20, 24
HC Wainwright & Co. Buy Aug 20, 24
Goldman Sachs Neutral Aug 2, 24
Cantor Fitzgerald Overweight Jul 16, 24
HC Wainwright & Co. Buy Jul 9, 24
HC Wainwright & Co. Buy May 8, 24
Mizuho Neutral May 8, 24
Mizuho Neutral Mar 4, 24
HC Wainwright & Co. Buy Mar 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dolmetsch Ricardo President, R&D President, R&D Sep 18 Sell 7.46 5,841 43,574 163,404 09/20/23
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jul 10 Sell 11.36 15,117 171,729 95,098 07/12/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Mar 07 Sell 21.36 585 12,496 90,381 03/09/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Option 5.31 37,762 200,516 122,554 07/29/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Sell 25 37,762 944,050 95,196 07/29/22
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jun 16 Sell 13.21 7,575 100,066 64,511 06/21/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jun 16 Sell 13.20 1,687 22,268 104,688 06/21/22
POST LEONARD E Director Director Feb 28 Sell 16.64 795 13,229 3,121 03/02/22
Kaye Jack Director Director Feb 28 Sell 16.76 600 10,056 19,003 03/02/22
Springhorn Jeremy P. Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Meek David D. Director Director Feb 28 Sell 16.7 602 10,053 7,380 03/02/22
Balachandran Madhavan Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Soteropoulos Paula Director Director Feb 28 Sell 16.87 596 10,055 7,302 03/02/22
Dolmetsch Ricardo President, R&D President, R&D Feb 28 Sell 16.68 1,484 24,753 122,325 03/02/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.8 4,075 68,460 106,375 03/02/22
Gut Robert Director Director Jan 26 Sell 18.12 2,348 42,546 35,153 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jan 26 Sell 18.02 2,945 53,069 63,697 01/28/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jan 26 Sell 18.03 3,963 71,453 66,820 01/28/22
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Jan 26 Sell 18.1 10,901 197,308 245,676 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Option 5.31 6,000 31,860 72,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Sell 27.9 6,000 167,400 66,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Sell 36.32 6,000 217,920 68,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Option 5.31 6,000 31,860 74,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Option 5.31 6,000 31,860 74,871 05/18/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Sell 31.66 6,000 189,960 68,871 05/18/21
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Dec 21 Option 7.53 12,501 94,133 277,738 12/21/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Option 7.53 3,216 24,216 283,780 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Sell 43.93 10,313 453,050 273,467 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Sep 18 Sell 41.28 7,500 309,600 285,814 09/18/20